A carregar...
Will the PCSK9 Inhibitors Be Employers’ “Line in the Sand”?
After the introductions of sofosbuvir (Sovaldi) and ledipasvir plus sofosbuvir (Harvoni) for the treatment of hepatitis C, employers have become very sensitive to new, and especially unforeseen, factors that significantly raise healthcare costs. With the recent launch of the proprotein convertase su...
Na minha lista:
| Publicado no: | Am Health Drug Benefits |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Engage Healthcare Communications, LLC
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5004813/ https://ncbi.nlm.nih.gov/pubmed/27606041 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|